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C A S E R E P O R T
A 24-year-old male patient with acute myeloid
leukemia (AML), who had been in remission for
18 months following the completion of chemo-
therapy, presented with fatigue and nasal bleed-
ing. He was found to have pancytopenia, and bone
marrow aspiration showed relapsed AML. He was
given high-dose sequential chemotherapy consist-
ing of cytosine arabinoside, 500 mg/m2 per day as
a 24-h continuous infusion, idarubicin, 12 mg/m2
per day on days 1–3, etoposide, 200 mg/m2 per
day as a 24-h continuous infusion on days 8–10,
and granulocyte colony-stimulating factor (G-
CSF), 5 mg/kg per day subcutaneously, starting
from day 12 until absolute neutrophil recovery
above 1000/mL. The patient became neutropenic,
with a count below 100/mL, on the 5th day of
chemotherapy. He was pyrexial on the next day,
with a temperature of 39 8C, without any localizing
symptoms or signs of infection. Blood cultures
were taken, and chest X-ray was normal. Empirical
antibiotic therapy with piperacillin–tazobactam
was commenced, and vancomycin was added
48 h later, when no response was obtained. Exam-
ination revealed widespread oral mucositis on the
fourth day of the febrile neutropenic episode.
Blood cultures, which had been taken every other
febrile day, revealed extended-spectrum b-lacta-
mase-producing Escherichia coli on the seventh
day of pyrexia, and meropenem and amikacin
were substituted for piperacillin–tazobactam.
Total parenteral nutrition was also commenced
on the same date, as the patient now suffered from
severe dysphagia and could not tolerate any oral
intake. Fever and dysphagia continued, and an
endoscopy was performed, revealing esophageal
candidiasis on the 12th day of pyrexia. Flucona-
zole, 6 mg/kg per day, was commenced intrave-
nously. A non-albicans Candida sp. was grown in
both esophageal and blood cultures on the 14th
day of pyrexia, and fluconazole was changed to
amphotericin B deoxycholate, 0.7 mg/kg per day,
due to continuing pyrexia and the possibility of a
fluconazole-resistant Candida sp. Surprisingly, two
different non-albicans Candida species were identi-
fied later, with esophageal cultures revealing C.
krusei, whereas blood cultures yielded C. kefyr with
a fluconazole MIC of 4 mg/L and an amphotericin
B deoxycholate MIC of 0.25 mg/L. Fundoscopic
examination was negative for candida retinitis.
The patient’s neutrophil count rose above 500/
mL on the 19th day of pyrexia (25th day following
chemotherapy). Mucositis and dysphagia gradu-
ally resolved with a subsequent increase in the oral
intake, and parenteral nutrition was terminated.
However, pyrexia reaching 39 8C continued.
Amphotericin B deoxycholate was replaced with
liposomal amphotericin B, 100 mg, daily due to
hypokalemia refractory to intravenous replace-
ment therapy, and meropenem, amikacin and
vancomycin treatment was terminated on the
26th day of pyrexia. The patient remained febrile,
and liver transaminase levels were found to be
elevated. Abdominal CT on the 33rd day of pyr-
exia demonstrated numerous, prominent hypo-
dense lesions within the spleen, and few lesions
in the liver and kidneys, consistent with abscesses.
A diagnosis of chronic disseminated candidiasis
(CDC) was made. A bone marrow aspirate at this
stage confirmed that the patient’s AML was still
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in remission. He remained febrile with no change
in his clinical condition after a total of 45 days of
therapy (24 days and 1.2-g total dose of amphoter-
icin B deoxycholate, and 21 days and 2.1-g total
dose of liposomal amphotericin B). A control
abdominal CT on the 55th day of pyrexia revealed
no improvement of the lesions.
Q U E S T I O N S
1. How would you proceed at this stage?
2. What is the role of different forms of amphoter-
icin B in the management of CDC?
3. What is the role of fluconazole in the manage-
ment of CDC?
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